TP53 and breast cancer: The implications of these findings for human breast cancer are obvious, since both TP53 and PTEN are most commonly mutated in triple-negative breast cancers, although in the TCGA data, combined inactivation of TP53 and PTEN occurs in less than 2.5% of cases (Cancer Genome Atlas Network, 2012).